STK39 Polymorphism Is Associated with Essential Hypertension: A Systematic Review and Meta-Analysis

Bo Xi¹,², Man Chen², Giriraj R Chandak³, Yue Shen⁴, Li Yan⁵, Juan He⁶, Si-Hua Mou⁷, Man Chen², Giriraj R Chandak³, Yue Shen⁴, Li Yan⁵, Juan He⁶, Si-Hua Mou⁷

¹ Institute of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, People's Republic of China, ² School of Laboratory Medicine, Chengdu Medical College, Chengdu, People's Republic of China, ³ Centre for Cellular and Molecular Biology, Council of Scientific and Industrial Research, Hyderabad, India, ⁴ Department of Epidemiology, Capital Institute of Pediatrics, Beijing, People's Republic of China, ⁵ Department of Social Medicine and Health Service Management, Dalian Medical University, Dalian, People's Republic of China, ⁶ Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, People's Republic of China, ⁷ Department of Clinical Laboratory, Taizhou Municipal Hospital, Taizhou, People's Republic of China

Abstract

Background: A recent genome-wide association study identified STK39 as a candidate gene for blood pressure (BP) in Europeans. Subsequently, several studies have attempted to replicate the association across different ethnic populations. However, the results have been inconsistent.

Objective and Methods: We performed a meta-analysis to elucidate the association between the STK39 rs3754777 polymorphism (or proxy) and hypertension. Published literature from PubMed and Embase databases were retrieved and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model.

Results: Using appropriate inclusion/exclusion criteria, we identified 10 studies that included 21,863 hypertensive cases and 24,480 controls from different ethnicities. The meta-analysis showed a significant association of STK39 rs3754777 variant with hypertension (OR = 1.10, 95%CI = 1.06–1.15, p = 7.95 × 10⁻⁶). Further subgroup analysis by ethnicity suggested that the association was significant in Europeans (OR = 1.08, 95% CI = 1.03–1.14, p = 0.002) and in East Asians (OR = 1.16, 95%CI = 1.07–1.25, p = 4.34 × 10⁻⁴), but not in Africans (OR = 1.01, 95%CI 0.80–1.27, p = 0.932). We further confirmed the positive association by sensitivity analysis. No publication bias was detected (Begg’s test, p = 0.721; Egger’s test, p = 0.744).

Conclusions: The present meta-analysis confirms the significant association of STK39 polymorphism with susceptibility to hypertension in Europeans and East Asians. Future studies should include gene–gene and gene–environment interactions to investigate the identified association.

Introduction

Hypertension, whose prevalence has increased dramatically in last few years [1,2], is a major risk factor for cardiovascular disease and end-stage renal damage and ultimately increases mortality worldwide [3]. Hypertension is influenced by both genetic and environmental factors, as well as their interactions [4]. As per current evidence, genetic factors are estimated to account for approximately 30%–50% of variation in blood pressure (BP) levels [5].

Recently, several genome wide association studies (GWASs) have identified a host of BP/hypertension related loci in Europeans [6–11]. Two meta-analyses further confirmed several but not all the loci in East Asians [12,13]. In 2009, serine/threonine kinase 39 (STK39) was reported as a candidate gene for BP in a GWAS on American Old Order Amish individuals [9]. In this study, a cluster of single nucleotide polymorphisms (SNPs) in the STK39 gene were indicated to be associated with BP and two of the SNPs, rs3754777 and rs6749447 variants were replicated in an independent Amish sample, in four non-Amish Caucasian populations [9] and in a study of 1017 African Americans [14]. Since then, six publications covering 11 studies have been conducted to investigate the association between STK39 variants and hypertension [15–19]. However, the results have been inconsistent.

Therefore, in this study, we performed a meta-analysis to further clarify the association between STK39 SNP and hypertension across different ethnic populations.

Materials and Methods

Strategy for Literature Search

We searched the literature databases including PubMed and Embase. The search strategy to identify all possible studies
involved the use of the following key words: (“Serine/threonine kinase 39” or “STK39”) and (“blood pressure” or “high blood pressure” or “hypertension”). The reference lists of retrieved articles were hand-searched. The literature search was updated on November 21, 2012.

Inclusion Criteria and Data Extraction

The studies were included in the meta-analysis based on the following inclusion criteria: (1) evaluated the association of STK39 SNP with hypertension; (2) used case-control or cohort design; (3) provided sufficient data for calculation of odds ratio (OR) or relative risk (RR) with 95% confidence interval (CI), e.g., provided the genotype frequencies of the studied SNP in hypertensive cases and controls. The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country of origin; (4) ethnicity of the study population; (5) number of subjects under hypertensive cases and controls; (6) OR or RR with 95% CI; (7) diagnostic criteria for hypertensive cases and controls; (8) covariates adjustment; (9) SNPs analyzed. Two authors independently assessed the articles for compliance with the inclusion/exclusion criteria, resolved disagreements and reached a consistent decision.

Statistical Analysis

The genotypes of studied SNP was in Hardy-Weinberg equilibrium in controls of all included studies as reported by the individual studies ($p>0.05$). We investigated the association of STK39 SNP with hypertension by calculating pooled OR and 95% CI. The significance of pooled OR was determined by $Z$ test ($p<0.05$ was considered statistically significant). Cochran's Q test was performed to evaluate the heterogeneity between studies. A random- (DerSimonian-Laird method [20]) or fixed- (Mantel-Haenszel method [21]) effects model was used to calculate pooled OR in the presence ($p<0.10$) or absence ($p>0.10$) of heterogeneity, respectively. Similar approach was used for performing subgroup analysis by ethnicity. Sensitivity analysis by removing one study at a time was performed to evaluate the stability of the results. Publication bias was assessed by Begg's test [22] and Egger's test [23] ($p<0.05$ was considered statistically significant). All statistical analyses were performed using STATA version 11 (StataCorp LP, College Station, Texas, USA).

Results

Characteristics of the Studies

A flow chart describing the exclusion/inclusion of individual articles (or studies) has been presented as Figure 1. The comprehensive literature search identified a total of 80 potentially relevant papers, of which 70 papers were excluded because of obvious irrelevance after reading the title and/or abstract. One paper was excluded because it examined the association between STK39 SNP and salt-sensitive hypertension [24]; another paper...
### Table 1. Characteristics of the studies included in the meta-analysis.

| Study                      | Country | Ethnicity | Sample size | Odds ratio | 95% confidence interval | Diagnostic criteria (mmHg) | Adjustment * | Studied | SNP     |
|---------------------------|---------|-----------|-------------|------------|-------------------------|---------------------------|--------------|---------|---------|
| Fava, 2011 (MDC-CVA) [15] | Sweden  | European  | 3566        | 1.151      | 1.016–1.305             | ≥140/90                  | 1, 2, 3, 4, 5 | rs35929607 |
| Fava, 2011 (MPP at baseline) [15] | Sweden  | European  | 6028        | 1.077      | 1.002–1.157             | ≥140/90                  | 1, 2, 3, 4, 5 | rs35929607 |
| Fava, 2011 (MPP at follow-up) [15] | Sweden  | European  | 6796        | 1.064      | 0.976–1.159             | ≥140/90                  | 1, 2, 3, 4, 5 | rs35929607 |
| Niu, 2011 [16]            | China   | East Asian| 548         | 1.143      | 0.952–1.371             | ≥140/90                  | 1, 2, 3, 4, 5 | rs35929607 |
| Chen, 2012 (Population1-Male) [17] | China   | East Asian| 335         | 1.283      | 0.996–1.652             | ≥140/90                  | 1, 3, 8, 9, 10 | rs3754777  |
| Chen, 2012 (Population1-Female) [17] | China   | East Asian| 266         | 0.906      | 0.667–1.230             | ≥140/90                  | 1, 3, 8, 9, 10 | rs3754777  |
| Chen, 2012 (Population2-Male) [17] | China   | East Asian| 1330        | 1.231      | 1.078–1.405             | ≥140/90                  | 1, 3, 8, 9, 10 | rs3754777  |
| Chen, 2012 (Population2-Female) [17] | China   | East Asian| 815         | 1.092      | 0.909–1.313             | ≥140/90                  | 1, 3, 8, 9, 10 | rs3754777  |
| Kidambi, 2012 [18]        | USA     | African   | 1155        | 1.010      | 0.804–1.269             | ≥140/90                  | Normal BP     | 1, 2, 3, 11 | rs2063958 |
| Xu, 2012 [19]             | China   | East Asian| 1024        | 1.091      | 0.815–1.461             | ≥140/90                  | 12, 13, 9, 10 | rs3754777  |

*S And/or current under antihypertensive treatment.

*In the lower third of the distribution of population blood pressures.

*1, age; 2, sex; 3, BMI; 4, heart rate; 5, interaction variables; 6, follow-up years; 7, BMI; 8, type 2 diabetes; 9, smoking; 10, alcohol drinking; 11, creatinine; 12, triglyceride; 13, high density lipoprotein; 14, total cholesterol.

doi:10.1371/journal.pone.0059584.t001
was excluded because it was an editorial comment [25]. Finally, 8 papers met the primary inclusion criteria, of which 3 papers were further excluded because they examined the association between \( STK39 \) SNP and BP only [9,14,26]. In addition, since more than one study was included in two papers by Fava et al. [15] and Chen et al. [17], they were considered as separate studies in data analysis. Therefore, 10 studies were included in the final meta-analysis [15–19]. Each study had analyzed different SNP or multiple SNPs in \( STK39 \), however, we selected only one SNP for meta-analysis. The rs3754777 SNP is known to be in high linkage disequilibrium with rs2063958 (\( r^2 \geq 0.95 \)) and rs35929607 (\( r^2 \geq 0.87 \)). The number of cases in the included studies ranged from 266 to 6796. All the studies defined hypertension as SBP/DBP \( \geq 140/90 \) mmHg or currently on antihypertensive drugs. Since most studies provided covariates-adjusted OR (or RR) with 95%CI under an additive model but not the genotype frequencies of studied SNP in hypertensive cases and controls, we only calculated the pooled OR with 95%CI under an additive model. The characteristics of the included studies are listed in Table 1.

### Meta-analysis Results

A total of 21,863 hypertensive cases and 24,480 controls were included in the meta-analysis. The results indicated that rs3754777 variant in \( STK39 \) was significantly associated with hypertension (OR = 1.10, 95%CI = 1.06–1.15, \( p = 7.95 \times 10^{-6} \); Figure 2), with no evidence of between-study heterogeneity (\( I^2 = 0.0\%, \ p = 0.548 \)). Further subgroup analysis by ethnicity showed that the association was significant in Europeans (OR = 1.08, 95% CI = 1.03–1.14, \( p = 0.002 \)) and in East Asians (OR = 1.16, 95%CI = 1.07–1.25, \( p = 4.34 \times 10^{-4} \)), but not in Africans (OR = 1.01, 95%CI = 0.80–1.27, \( p = 0.932 \)) (Figure 3).

### Sensitivity Analysis

Sensitivity analysis confirmed the significant association between rs3754777 SNP and hypertension, with OR and 95%CI ranging from 1.09 (1.04–1.14) to 1.11 (1.06–1.17). Additionally, Fava et al. [15] reported that after exclusion of 2398 subjects from the ‘Malmo Preventive Project’ (MPP) cohort, who also participated in the ‘Malmo Diet and Cancer-cardiovascular arm’ (MDG-CVA) cohort, the association between \( STK39 \) rs35929607 and hypertension was no longer statistically significant at baseline (OR = 1.06, 95% CI = 0.98–1.14) or at follow-up (OR = 1.06, 95% CI = 0.98–1.15). We then included the above data to re-analyze the association but the overall result did not change substantially (OR = 1.09, 95% CI 1.05–1.14).

### Publication Bias

Begg’s funnel plot was presented as Figure 4 and no publication bias was found (Begg’s test, \( p = 0.721 \); Egger’s test, \( p = 0.744 \)).

---

**Table 1. Characteristics of the included studies**

| Study | ID | OR (95% CI) | Weight |
|-------|----|-------------|--------|
| Fava, 2011 (MDC-CVA) [15] | 1.15 (1.02, 1.30) | 11.27 |
| Fava, 2011 (MPP at baseline) [15] | 1.08 (1.00, 1.16) | 34.13 |
| Fava, 2011 (MPP at follow-up) [15] | 1.06 (0.98, 1.16) | 23.91 |
| Niu, 2011 [16] | 1.14 (0.95, 1.37) | 5.31 |
| Chen, 2012 (Population 1-Male) [17] | 1.28 (1.00, 1.65) | 2.76 |
| Chen, 2012 (Population 1-Female) [17] | 0.91 (0.67, 1.23) | 1.89 |
| Chen, 2012 (Population 2-Male) [17] | 1.23 (1.08, 1.40) | 10.06 |
| Chen, 2012 (Population 2-Female) [17] | 1.09 (0.91, 1.31) | 5.22 |
| Kidambi, 2012 [18] | 1.01 (0.80, 1.27) | 3.39 |
| Xu, 2012 [19] | 1.09 (0.81, 1.46) | 2.07 |
| Overall (I-squared = 0.0%, \( p = 0.548 \)) | 1.10 (1.06, 1.15) | 100.00 |

**Figure 2. Meta-analysis of the association between \( STK39 \) rs3754777 variant and hypertension.**

doi:10.1371/journal.pone.0059584.g002
Discussion

To our knowledge, this is the first meta-analysis assessing the association between \textit{STK39} variants and hypertension. The result confirms that rs3754777 SNP in \textit{STK39} is significantly associated with hypertension, and is independent of conventional environmental factors such as age, sex, body mass index (BMI) and lifestyle factors. The association was significant in Europeans and East Asians, but not in Africans. Stability of the result by sensitivity analysis and no evidence of publication bias further confirm the significant association between \textit{STK39} rs3754777 SNP and hypertension.

The \textit{STK39} gene encodes the Ste20-related proline-alanine-rich kinase (SPAK) protein, which may regulate BP by increasing its expression and altering renal sodium excretion through its interaction with WNK kinase and cation-chloride cotransporters [27].Experimental studies have indicated that knock-in mice in which SPAK cannot be activated by WNKs showed significantly reduced BP that was salt-dependent [28]. Recently, two population-based studies have demonstrated that \textit{STK39} variants might be associated with salt sensitivity [15,24]. Thus, the above evidences support the idea that \textit{STK39} gene is involved in salt homeostasis and thereby BP regulation in humans.

Our study has several strengths and few limitations. First, we used the OR or RR with adjustment for confounding factors from individual study to calculate the pooled OR, which increased the accuracy of effect estimate. Second, the included studies provided data on large number of subjects and greatly improved the statistical power, which made the conclusion more convincing. Third, there was no evidence of between-study heterogeneity, suggesting the homogeneity of the study populations. However, because of inability to obtain raw data, we could perform only a study-level but not a patient-level meta-analysis, which would have enabled us to adjust for multiple risk factors. This remains one of the limitations of the study. In addition, we could not address the effect of gene–gene/gene–environment interactions in this meta-analysis, though several papers have reported the effect of interaction between \textit{STK39} SNP and sex [15,17], BMI [19] or hormone replacement therapy [15] on susceptibility to hypertension.

In conclusion, the present meta-analysis confirmed the significant association between \textit{STK39} variants and hypertension in Europeans and East Asians but not in the Africans. Large-scale prospective studies with consideration of gene–gene/environment interactions are required to further dissect the causal nature of identified association.

---

**Figure 3. Meta-analysis of the association between \textit{STK39}rs3754777 variant and hypertension stratified for ethnicity.**
doi:10.1371/journal.pone.0059584.g003

| Study ID | OR (95% CI) | Weight |
|----------|------------|--------|
| European |            |        |
| Fava, 2011 (MDC-CVA) [15] | 1.15 (1.02, 1.30) | 11.27 |
| Fava, 2011 (MPP at baseline) [15] | 1.08 (1.00, 1.16) | 34.13 |
| Fava, 2011 (MPP at follow-up) [15] | 1.06 (0.98, 1.16) | 23.91 |
| Subtotal | 1.08 (1.03, 1.14) | 69.31 |
| East Asian |            |        |
| Niu, 2011 [16] | 1.14 (0.95, 1.37) | 5.31 |
| Chen, 2012 (Population1-Male) [17] | 1.28 (1.00, 1.65) | 2.76 |
| Chen, 2012 (Population1-Female) [17] | 0.91 (0.67, 1.23) | 1.89 |
| Chen, 2012 (Population2-Male) [17] | 1.23 (1.08, 1.40) | 10.06 |
| Chen, 2012 (Population2-Female) [17] | 1.09 (0.91, 1.31) | 5.22 |
| Xu, 2012 [19] | 1.09 (0.81, 1.46) | 2.07 |
| Subtotal | 1.16 (1.07, 1.25) | 27.30 |
| African |            |        |
| Kidambi, 2012 [18] | 1.01 (0.80, 1.27) | 3.39 |
| Subtotal | 1.01 (0.80, 1.27) | 3.39 |
| Heterogeneity between groups: p = 0.319 |
| Overall | 1.10 (1.06, 1.15) | 100.00 |
Author Contributions
Conceived and designed the experiments: BX SHM. Performed the experiments: YS LY. Analyzed the data: GRC YS JH. Contributed reagents/materials/analysis tools: LY JH. Wrote the paper: BX MC GRC.

References
1. Xi B, Liang Y, Mi J (2012) Hypertension trends in Chinese children in the national surveys, 1993 to 2009. Int J Cardiol doi:10.1016/j.ijcard.2012.09.032.
2. Xi B, Liang Y, Reilly KH, Wang Q, Hu Y, et al. (2012) Trends in prevalence, awareness, treatment, and control of hypertension among Chinese adults 1991–2009. Int J Cardiol 156: 326–329.
3. Lauver CM, Hoorn SV, Rodgers A, International Society of Hypertension (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371: 1513–1518.
4. Xi B, Cheng H, Shen Y, Zhao X, Hou D, et al. (2012) Physical activity modifies the associations between genetic variants and hypertension in the Chinese children. Atherosclerosis 225: 376–380.
5. Tanira MO, Al Balushi KA (2005) Genetic variations related to hypertension: a review. J Hum Hypertens 19: 7–19.
6. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, et al. (2009) A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 41: 527–534.
7. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41: 666–670.
8. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, et al. (2009) Genome-wide association study of blood pressure and hypertension. Nat Genet 41: 677–680.
9. Wang Y, O'Connell JR, McArdle PF, Wade JR, Doreff SE, et al. (2009) Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A 106: 226–231.
10. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, et al. (2011) Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat Genet 43: 531–538.
11. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, et al. (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 476: 103–109.
12. Xi B, Tang W, Wang Q (2012) Polymorphism near the ATP2B1 gene is associated with hypertension risk in East Asians: A meta-analysis involving 15 969 cases and 18 529 controls. Blood Press 21: 134–138.
13. Xi B, Shen Y, Reilly KH, Wang X, Mi J (2013) Recapitulation of four hypertension susceptibility genes (CSK, CYP17A1, MTHFR, and FGFR5) in East Asians. Metabolism 62: 196–203.
14. Adeyemo A, Gery N, Chen G, Herbert A, Doumatey A, et al. (2009) A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet 5: e1000564.
15. Fava C, Danese E, Montagnana M, Sigfredo M, Almgren P, et al. (2011) Serine/threonine kinase 39 is a candidate gene for primary hypertension especially in women: results from two cohort studies in Swedes. J Hypertens 29: 484–491.
16. Niu WQ, Zhang Y, Ji KD, Gao PJ, Zhu DL (2011) Contribution of five top whole-genome association signals to hypertension in Han Chinese. J Hum Hypertens 25: 278–280.
17. Chen LY, Zhao WH, Tian W, Gao J, Ji WD, et al. (2012) STK39 is an independent risk factor for male hypertension in Han Chinese. J Hum Hypertens 26: 122–127.
18. Kildanbi S, Ghosh S, Kotchen JM, Grin CE, Krishnaswami S, et al. (2012) Non-replication study of a genome-wide association study for hypertension and blood pressure in African Americans. BMC Med Genet 13: 27.
19. Xu J, Ji LD, Zhang LN, Dong CZ, Fei LJ, et al. (2012) Lack of association between STK39 and hypertension in the Chinese population. J Hum Hypertens 26: 413–416.
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
21. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
22. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.
23. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
24. Rice MY, Yang SJ, Oh SW, Park Y, Kim CI, et al. (2011) Novel genetic variations associated with salt sensitivity in the Korean population. Hypertens Res 34: 606–611.
25. Persu A, Vikkula M (2011) A genome-wide association study-derived candidate gene seeks replication: STK39. J Hypertens 29: 434–436.
26. Cunningham MS, Kay C, Avery PJ, Mayosi BM, Korel MS, et al. (2009) STK39 polymorphisms and blood pressure: an association study in British Caucasians.

Figure 4. Funnel plot of the association between STK39 rs3754777 variant and hypertension. doi:10.1371/journal.pone.0059584.g004
27. Delpire E, Gagnon KRE (2008) SPAK and OSR1: STE20 kinases involved in the regulation of ion homeostasis and volume control in mammalian cells. Biochemical Journal 409: 321–331.

28. Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, et al. (2010) Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2: 63–75.